Skip to main content
Unmet needs page hero image. Patient portrayal.

 
When antihistamines alone aren't enough1
 

 

Patient portrayal.

Many patients take antihistamines but still struggle with chronic spontaneous urticaria (CSU)2,3

CSU symptoms can last months, years, or sometimes longer. It’s a long-term condition that requires continued management. When patients are unable to manage their symptoms, having CSU can feel frustrating.2,4–6

Angioedema associated with CSU is typically non life–threatening11

  • Typically, no risk of anaphylaxis. Angioedema in CSU does not usually involve airway compromise11

  • Angioedema involves sudden tissue swelling. Swelling commonly involves lower dermis and subcutaneous tissue or mucous membranes (eg, lips, eyelids)7,12

Patients with CSU experience a spontaneous occurrence of wheals, angioedema, or both due to no known external triggers.2,4,7,9,10 You play a crucial role in helping them understand the facts.

BTK plays a key role in CSU13

Resources for you and your patients

BTK, Bruton's tyrosine kinase; MOA, mechanism of action.
 
References: 1. Rhapsido. Prescribing information. Novartis Pharmaceuticals Corp. 2. Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389–401. doi:10.1111/all.15603 3. Data on file. CSU Prevalence & Uncontrolled Patients Claims. Novartis Pharmaceuticals Corp; April 2024. 4. Saini SS, Kaplan AP. Chronic spontaneous urticaria: the devil’s itch. J Allergy Clin Immunol Pract. 2018;6(4):1097–1106. doi:10.1016/j.jaip.2018.04.013 5. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–2016. doi:10.1111/all.13209 6. Goldstein S, Eftekhari S, Mitchell L, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99(12):1091–1098. doi:10.2340/00015555-3282 7. Zuberbier T, Latiff AHA, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi:10.1111/all.15090 8. Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(5):321–333. doi:10.1159/000507218 9. Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy. 2019;49(5):655–662. doi:10.1111/cea.13309 10. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14(6):100533. doi:10.1016/j.waojou.2021.100533 11. Powell RJ, Leech SC, Till S, Huber PAJ, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547–565. doi:10.1111/cea.12494 12. Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. doi:10.1038/s41572-022-00389-z 13. Bernstein JA, Maurer M, Saini SS. BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229–1240. doi:10.1016/j.jaci.2023.12.008